Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.
OBJECTIVE
Platelets are stored routinely for 5 days or less and extended platelet storage time could improve product availability. This study compared platelet count increments (CI24hs) of riboflavin plus UV-light (PRT) treated platelet products in platelet additive solution stored for 5 days or less to products stored for 6-7 days.


METHODS
This was a retrospective study comparing CI24hs between two groups. Hematology patients received PRT treated platelet products stored for <5 days, or for 6-7 days. Platelet counts and adverse events during and up to 24 hours after transfusion were recorded and compared between the groups.


RESULTS
Ninety-seven patients received 168 transfusions of <5 day old PRT-treated platelets and 49 patients received 74 transfusions of 6-7 day old PRT-treated platelets. There was no statistically significant difference in CI24hs between the <5 day (median 6000) and 6-7 day storage group (median 8000) (p-value = 0.509). One mild fever was documented in the <5 day storage group.


CONCLUSIONS
CI24hs are similar for PRT-treated PLTs stored in PAS for <5 or 6-7 days. Studies to further evaluate clinical outcomes such as bleeding are ongoing.
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.
Alesia
A
Kaplan
Biostatistics and Bioinformatics Core of the Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Bruce
B
Lindgren
Terumo BCT, Lakewood, CO, USA.
Susanne
S
Marschner
Department of Hemathology and Hemotherapy, Transfusion Medicine Service, Hospital Complex of Navarre, Pamplona, Navarre, Spain.
Marivi
M
Aznar
Department of Hemathology and Hemotherapy, Transfusion Medicine Service, Hospital Complex of Navarre, Pamplona, Navarre, Spain.
Saioa
S
Zalba
Department of Hemathology and Hemotherapy, Transfusion Medicine Service, Hospital Complex of Navarre, Pamplona, Navarre, Spain.
Piva
P
Sánchez
Banco de Sangre y Tejidos de Navarra, Pamplona, Spain.
María Luisa
ML
Ayape
Department of Hemathology and Hemotherapy, Transfusion Medicine Service, Hospital Complex of Navarre, Pamplona, Navarre, Spain.
Eduardo
E
Olavarría
Department of Hemathology and Hemotherapy, Transfusion Medicine Service, Hospital Complex of Navarre, Pamplona, Navarre, Spain. Electronic address: manteloc@cfnavarra.es.
Maria Luisa
ML
Antelo
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets; D001793:Blood Preservation / Q000379:methods*; D058731:Blood Safety / Q000379:methods*; D004203:Disinfection / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D012256:Riboflavin / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors; D014466:Ultraviolet Rays
D012256:Riboflavin
CI(24hs); Extended storage; Pathogen reduction technology (PRT); Platelets; Riboflavin